Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.76

+0.7%

2:14 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (405)	9/29/1999 11:39:00 PM
From: Vector1	Read Replies (1) of 52153

Wow, David that post was from 1997. I still stand by it. I believe that Bex will be a $300m drug 3 to 4 years after approval. That is if they can ever get the BLA filing accepted. I guess you have to walk before you can run. Bex will have less of a lead over Y2B8 assuming that drug is approvable but from the data I have seen Bex is superior in both efficacy as well as fewer side effects. IDPH should report on its multi center phase III for Y2B8 in Q1 2000. The data from those trials will be very telling. v1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next